Ramosetron

Ramosetron is a 5-HT3 receptor antagonist belonging to Antiemetic agent.

Ramosetron is a selective 5-HT3 antagonist used as an antiemetic for chemotherapy- and postoperative-associated nausea and vomiting. It may also possess efficacy in irritable bowel syndrome.

Ramosetron is Metabolized via Hepatic metabolism mainly via CYP1A2 and CYP2D6 enzymes. It is mainly Excreted in urine as unchanged drug (16-22% within 24 hours following IV admin), demethylated and hydroxylated metabolites and their conjugates.

Ramosetron shows common side effects like Headache, Constipation, Chest discomfort.

Ramosetron is available in the form of Oral Tablet and Injectable solution.

Ramosetron is available in India, Japan, Malaysia, Singapore, and Philippines.

Ramosetron is an Antiemetic agent belonging to the class 5-HT3 receptor antagonist.

Ramosetron is a 5-HT3 receptor antagonist. It exerts its antiemetic property by blocking of serotonin to 5-HT3 receptors present in the afferent vagal nerve-endings in the GI mucosa.

The Onset of action of Ramosetron is not clinically established.

The Duration of action of Ramosetron to be approximately 48 hours.

Ramosetron is available in the form of Oral Tablet and Injectable solution.

Ramosetron tablet taken orally while injectable solution is given via intravenous route, once daily.

Ramosetron is an antiemetic drug used to prevent nausea and vomiting associated with cancer chemotherapy. It is also used for the treatment of diarrhea associated with irritable bowel syndrome. This medicine is not recommended for use in patients less than 18 years of age.

Ramosetron is a 5-HT3 receptor antagonist belonging to Antiemetic agent.

Ramosetron is a 5-HT3 receptor antagonist. It exerts its antiemetic property by blocking serotonin to 5-HT3 receptors present in the afferent vagal nerve-endings in the GI mucosa.

Ramosetron is approved for use in the following clinical indications

• Prevention of chemotherapy-induced or postoperative nausea and vomiting
• Treatment of irritable bowel syndrome with diarrhea.

• Nausea and vomiting associated with cancer chemotherapy

Intravenous Adult Dose: 300 mcg once daily. May administer an additional dose of 300 mcg if necessary. Max: 600 mcg/day.

• Nausea and vomiting associated with cancer chemotherapy

Oral Adult Dose: 100 mcg once daily.

• Irritable bowel syndrome in men

Oral Adult Dose: 5 mcg once daily, may adjust dose according to symptoms. Max: 10 mcg/day.

Ramosetron is available in various strengths as 300 mcg/2 mL (2 mL), 2.5 mcg, 5 mcg, 100 mcg.

Ramosetron is available in the form of Oral Tablet and Injectable solution.

• Constipation

This medicine should be used with caution in patients with constipation due to the increased risk of worsening of the patient's condition. Appropriate corrective measures, dose adjustments, or replacement with a suitable alternative may be necessary in some cases.

• Other medicines

Ramosetron may interact with many other medicines and may cause severe adverse effects. Hence, it is advised that you inform the doctor about all your current medicines including any herbs and supplements before beginning treatment with this medicine.

• Liver Disease

This medicine should be used with caution in patients with liver diseases due to the increased risk of adverse effects. Regular monitoring of liver function tests is necessary for such patients. Appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition.

• Kidney Disease

This medicine should be used with caution in patients with kidney diseases due to the increased risk of adverse effects. Regular monitoring of kidney function tests is necessary for such patients. Appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition.

Ramosetron is not recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be considered before taking or receiving this medicine.

Ramosetron is not recommended for use in pregnant women unless necessary. All the risks and benefits should be considered before taking or receiving this medicine.

Avoid food with strong flavours and fried food.

Common

Headache, diarrhoea, constipation, rash, itching, redness, heat, hot flushes, hiccup, numbness of tongue, hepatic dysfunction (increased AST, ALT, GPT, and bilirubin), increased BUN, epileptiform attacks, Shock or anaphylactoid.

• Abametapir: The serum concentration of Ramosetron can be increased when it is combined with Abametapir.
• Abatacept: The metabolism of Ramosetron can be increased when combined with Abatacept.
• Abiraterone: The serum concentration of Ramosetron can be increased when it is combined with Abiraterone.
• Acenocoumarol: The metabolism of Ramosetron can be decreased when combined with Acenocoumarol.
• Acetaminophen: The metabolism of Ramosetron can be decreased when combined with Acetaminophen.
• Acetazolamide: The risk or severity of CNS depression can be increased when Acetazolamide is combined with Ramosetron.
• Acetophenazine: The risk or severity of CNS depression can be increased when Acetophenazine is combined with Ramosetron.
• Aclidinium: The risk or severity of constipation can be increased when Aclidinium is combined with Ramosetron.
• Acyclovir: The metabolism of Ramosetron can be decreased when combined with Acyclovir.

The common side effects of Ramosetron include the following

• Common side effects

Headache, Constipation, Chest discomfort.

• Rare side effects

Skin rash, Redness of skin, Hiccups, Wheezing, Difficulty in breathing.

• Pregnancy

Pregnancy Category C

Ramosetron is not recommended for use in pregnant women unless necessary. All the risks and benefits should be considered before taking or receiving this medicine.

• Nursing Mothers

Ramosetron is not recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be considered before taking or receiving this medicine.

• Pediatric Use

Ramosetron is not recommended for use in patients under 18 years of age since the safety and efficacy of use are not clinically established.

• Pharmacodynamic

Information not available.

• Pharmacokinetics

Absorption

Information not available.

Distribution

Information not available.

Metabolism and Excretion

Ramosetron is Metabolized via Hepatic metabolism mainly via CYP1A2 and CYP2D6 enzymes. It is mainly Excreted in urine as unchanged drug (16-22% within 24 hours following IV admin), demethylated and hydroxylated metabolites and their conjugates.

• https://www.uptodate.com/contents/ramosetron-international-drug-information-concise?search=ramosetron&source=panel_search_result&selectedTitle=1~7&usage_type=panel&kp_tab=drug_international&display_rank=1
• https://go.drugbank.com/drugs/DB09290
• https://www.apollopharmacy.in/salt/RAMOSETRON